Honda M, Takasaki E, Suzuki T, Maeda S, Imai T, Hosoya Y, Chen J A
Dept. of Urology, Dokkyo University School of Medicine.
Gan To Kagaku Ryoho. 1995 Jan;22(1):105-9.
We evaluated the usefulness of hormonal therapy combined with UFT as initial treatment in comparison with hormonal therapy alone in 92 patients with Stage D2 prostatic cancer treated at the Department of Urology, Dokkyo University School of Medicine between 1974 and 1993. Twenty-six of these patients were treated with diethylstilbestrol diphosphate (DESP) and castration (hormonal therapy alone group), and 23 patients were treated with UFT, DESP and castration (UFT combined therapy group). The 5-year survival rates calculated with Kaplan-Meier's method in the hormonal therapy alone group and the UFT combined therapy group were 34.6 % and 38.3%, respectively. However, the 3-year survival rates of pathologically poorly differentiated adenocarcinoma in these groups were 30.0% and 50.0%, respectively. Based on these results, it was suggested that UFT administration combined with hormonal therapy is useful for pathologically poorly differentiated adenocarcinoma in Stage D2 prostatic cancer.
1974年至1993年间，在独协医科大学泌尿外科接受治疗的92例D2期前列腺癌患者中，我们评估了激素疗法联合优福定作为初始治疗与单纯激素疗法相比的有效性。其中26例患者接受己烯雌酚二磷酸酯（DESP）和去势治疗（单纯激素疗法组），23例患者接受优福定、DESP和去势治疗（优福定联合治疗组）。采用Kaplan-Meier法计算，单纯激素疗法组和优福定联合治疗组的5年生存率分别为34.6%和38.3%。然而，这些组中病理低分化腺癌的3年生存率分别为30.0%和50.0%。基于这些结果，提示优福定联合激素疗法对D2期前列腺癌病理低分化腺癌有效。
